Comparative Efficacy of Calcium Antagonists and Beta Blockers in Essential Hypertension

1986 ◽  
pp. 213-220
Author(s):  
A. E. Doyle
Keyword(s):  
Essential Hypertension ◽  
Calcium Antagonists ◽  
Beta Blockers ◽  
Comparative Efficacy

Comparative efficacy and tolerability of two long-acting calcium antagonists, mibefradil and amlodipine, in essential hypertension

1997 ◽  
Vol 19 (6) ◽  
pp. 1368-1378 ◽  
Author(s):  
Fred E. Karch ◽  
Robert Pordy ◽  
Joan Ryder Benz ◽  
Albert Carr ◽  
N.Martin Lunde ◽  
...  
Keyword(s):  
Essential Hypertension ◽  
Calcium Antagonists ◽  
Comparative Efficacy ◽  
Long Acting

Comparative efficacy and safety of preserved versus preservative‐free beta‐blockers in patients with glaucoma or ocular hypertension: a systematic review

2021 ◽  
Author(s):  
Anne Guldhammer Skov ◽  
Amalie Santaolalla Rives ◽  
Josefine Freiberg ◽  
Gianni Virgili ◽  
Augusto Azuara‐Blanco ◽  
...  
Keyword(s):  
Systematic Review ◽  
Ocular Hypertension ◽  
Beta Blockers ◽  
Efficacy And Safety ◽  
Comparative Efficacy ◽  
Preservative Free

The Transient Anti-Hypertensive Effect of Phentolamine in Patients Receiving Beta-Blocker Treatment

1973 ◽  
Vol 1 (2) ◽  
pp. 462-464
Author(s):  
Ann Dawson ◽  
Ian Smith ◽  
Brian F Johnson
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Essential Hypertension ◽  
Beta Blocker ◽  
Peak Plasma ◽  
Beta Blockers ◽  
Peak Plasma Concentration ◽  
Hypotensive Effect ◽  
Additional Reduction ◽  
Standing Blood Pressure

In seven hypertensives receiving beta-blocker drugs, an additional reduction in standing blood pressure occurred between 60 and 90 minutes after 40 mg phentolamine by mouth. The occurrence of the postural hypotensive effect was delayed in relation to the reported time of peak plasma concentration of unchanged phentolamine. Supine blood pressure and heart rate were unaffected. Phentolamine has no clinically useful anti-hypertensive effect in conjunction with beta-blockers in patients with essential hypertension.

1422Prevalence and characteristics of medication non-adherence assessed by quantitative liquid chromatography-tandem mass spectrometry in patients with hypertension

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
M E A M Van Kleef ◽  
E M Van Maarseveen ◽  
F L J Visseren ◽  
P J Blankestijn ◽  
M L Bots ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Tandem Mass Spectrometry ◽  
Calcium Antagonists ◽  
Clinical Characteristics ◽  
Antihypertensive Medication ◽  
Beta Blockers ◽  
Tandem Mass ◽  
Hypertensive Patients ◽  
Chromatography Tandem Mass Spectrometry ◽  
Quantitative Screening

Abstract Background/Introduction Antihypertensive medication screening by qualitative high performance chromatography-tandem mass spectrometry (LC-MS/MS) has recently become available to detect non-adherence to antihypertensive treatment. Because the result of this test is dichotomous (the drug is detected or not), it may incorrectly classify patients who take their medications infrequently. Therefore, a quantitative screening method has been developed to improve detection of non-adherence. Purpose The aim of this study was to determine the prevalence of medication non-adherence assessed by quantitative LC-MS/MS in referred hypertensive patients. In addition, we determined to what extent clinical characteristics, prescribed medication and self-reported perspectives, were associated with medication non-adherence assessed by quantitative LC-MS/MS. Methods In this cross-sectional study we included 197 newly referred hypertensive patients (mean age 56±14 years, 101 women, mean 24-hour ambulatory blood pressure 143/85±21/12 mmHg) prescribed at least one antihypertensive drug. Medication adherence was assessed by quantitative LC-MS/MS in plasma. The concentration of each prescribed drug (or its metabolite) was measured and divided by the literature-based population trough concentration, to get the concentration ratio (CR). If the CR of at least one of the prescribed drugs was ≤0.3 the patient was categorized as non-adherent: completely non-adherent if all were ≤0.3, partially non-adherent if not all were ≤0.3. Logistic regression analysis was performed to determine the association between clinical characteristics, prescribed medication and self-reported compliance (Hill & Bone), relational empathy (CARE) and beliefs about medicines (BMQ), and medication non-adherence. Results 29% was classified as partially non-adherent and 10% as completely non-adherent. Non-adherence to calcium antagonists (30%) and beta blockers (24%) prevailed non-adherence to other antihypertensive medication classes (6–11%). The odds of non-adherence were higher in patients with apparent resistant hypertension and increased with the number of antihypertensive medication types, tablets and daily defined dose prescribed (Figure 1). Combination pills were inversely associated with non-adherence. Self-reported measures were not associated. Older age was negatively associated with non-adherence to RAS inhibitors (OR 0.60, 95% CI 0.36–0.96) and beta blockers (OR 0.50, 95% CI 0.30–0.77). Figure 1 Conclusions Quantitative screening by LC-MS/MS in plasma shows a high prevalence of non-adherence in referred hypertensive patients, particularly for calcium antagonists and beta blockers. The observation that clinical characteristics and self-reported perspectives about medical treatment were not associated with non-adherence, supports the use of quantitative LC-MS/MS to detect non-adherence to antihypertensive medication in daily practice.

Sign in / Sign up

Export Citation Format

Share Document